AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10971238
Drug: Propofol plus
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol plus midazolam (n=119, group B, initial midazolam dose of 2.5-3.5 mg IV, followed by repeated doses of 20 mg of propofol)
Trial: 1310922
Drug: L-(−)-Ephedrine hydrochloride
RxNorm normalized name: L-Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-(−)-Ephedrine hydrochloride (50 mg three times a day)
Trial: 26672637
Drug: Somavaratan 1.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somavaratan 1.15 mg/kg weekly
Trial: 26672637
Drug: Somavaratan 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somavaratan 2.5 mg/kg twice monthly
Trial: 26672637
Drug: Somavaratan 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somavaratan 5.0 mg/kg monthly
Trial: 22497929
Drug: Prehospital stroke
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prehospital stroke treatment in a mobile stroke unit (MSU)
Trial: 22497929
Drug: Optimised conventional
RxNorm normalized name: Optimised human arginase I
DrugBank: Pegzilarginase (DB14780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimised conventional hospital-based stroke treatment (control group)
Trial: 9041371
Drug: Pancreatic clamping
RxNorm normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancreatic clamping with constant insulin levels
Trial: 8105678
Drug: 3-day treatment
RxNorm normalized name: Gyne-Lotrimin 2% 3-Day Treatment Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day treatment with amoxicillin and clavulanate potassium (20 mg/kg per day of amoxicillin and 5 mg/kg per day of clavulanate potassium in three divided doses)
Trial: 8105678
Drug: 10-day treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day treatment with amoxicillin and clavulanate potassium (20 mg/kg per day of amoxicillin and 5 mg/kg per day of clavulanate potassium in three divided doses)
Trial: 3690939
Drug: Digoxin, 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin, 1.0 mg intravenously
Trial: 25705798
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg yohimbine HCl
Trial: 18496183
Drug: rFVIIa (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rFVIIa (combined treatment group)
Trial: 14712893
Drug: Antiplatelet agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet agents (specific agents not mentioned)
Trial: 14712893
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of antiplatelet agents (specific agents not mentioned)
Trial: 10925615
Drug: Single radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single radiation dose of 8 Gy
Trial: 10925615
Drug: Ten treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ten treatments of 3 Gy delivered over two weeks
Trial: 8922218
Drug: Fluid infusion
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid infusion pump pressures maintained below women's mean arterial pressures (MAPs)
Trial: 8922218
Drug: Fluid infusion
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid infusion pump pressures set at random
Trial: 1565267
Drug: Thymopentin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymopentin (50 mg) given three times before surgery and three times after surgery
Trial: 22626675
Drug: 3.75 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 μg of antigen with half the standard dose of MF59 adjuvant
Trial: 22626675
Drug: 7.5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 μg of antigen with a full dose of MF59 adjuvant
Trial: 22626675
Drug: Non-adjuvanted vaccine
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adjuvanted vaccine containing 15 μg of antigen
Trial: 22626675
Drug: 3.75 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 μg adjuvanted formulation
Trial: 22626675
Drug: 7.5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 μg adjuvanted formulation
Trial: 22626675
Drug: Booster vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster vaccination with seasonal influenza vaccine
Trial: 11789969
Drug: Cilostazol 100
RxNorm normalized name: cilostazol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol 100 mg bid
Trial: 18166097
Drug: Periodontal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodontal therapy (scaling and root planing)
Trial: 17149989
Drug: Caffeine supplementation
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine supplementation (201 mg of caffeine per day)
Trial: 17149989
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 pills per day)
Trial: 14976565
Drug: RAC4 (rabeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAC4 (rabeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 4 days)
Trial: 14976565
Drug: RAC7 (rabeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAC7 (rabeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 7 days)
Trial: 14976565
Drug: OAC7 (omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC7 (omeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 7 days)
Trial: 16917623
Drug: Bromazepam 6
RxNorm normalized name: bromazepam 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromazepam 6 mg
Trial: 1329159
Drug: Bromazepam 12
RxNorm normalized name: bromazepam 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromazepam 12 mg
Trial: 29059600
Drug: 17alpha‐methyltestosterone (MT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17alpha‐methyltestosterone (MT) at 15.0 mg/kg (T3)
Trial: 29059600
Drug: 17alpha‐methyltestosterone (MT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17alpha‐methyltestosterone (MT) at 30.0 mg/kg (T4)
Trial: 29059600
Drug: 17alpha‐methyltestosterone (MT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17alpha‐methyltestosterone (MT) at 0.3 mg/kg (T1)
Trial: 29059600
Drug: 17alpha‐methyltestosterone (MT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17alpha‐methyltestosterone (MT) at 3.0 mg/kg (T2)
Trial: 29059600
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no hormone)
Trial: 26574050
Drug: Exercise intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exercise intervention (60 minutes general fitness class, 40 minutes endurance training/aerobic, 20 minutes strength training and stretching/relaxation, performed at least twice per week for a minimum of 12 weeks)
Trial: 10591360
Drug: ramosetron 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ramosetron 0.3 mg
Trial: 22358123
Drug: ramosetron 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ramosetron 0.3 mg combined with dexamethasone 8 mg
Trial: 12463731
Drug: Nateglinide (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide (120 mg, 10 min before meals for 4 days) + Warfarin (30 mg on the second day)
Trial: 24142206
Drug: Warfarin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (30 mg) alone
Trial: 12463731
Drug: Nateglinide +
RxNorm normalized name: Nateglinide
DrugBank: Nateglinide (DB00731)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nateglinide + Warfarin
Trial: 10513507
Drug: Ibuprofen 2,400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 2,400 mg/day for 28 days
Trial: 7695978
Drug: Carboplatin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (400 mg/m2 intravenous day 1) and Etoposide (100 mg/m2 intravenous days 1 to > 3)
Trial: 1710750
Drug: Alfuzosin (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin (daily dose 7.5‐10 mg)
Trial: 7464561
Drug: Colestipol (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colestipol (30 g/day)
Trial: 24382002
Drug: Romosozumab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Romosozumab (all doses)
Trial: 20025373
Drug: Guided self‐change
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided self‐change (GSC) treatment in group format
Trial: 20025373
Drug: Guided self‐change
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided self‐change (GSC) treatment in individual format
Trial: 17434635
Drug: Oral Amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Amiodarone (600 mg in three divided doses)
Trial: 17434635
Drug: Intravenous Amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Amiodarone (5 mg/kg over 30 min followed by 1000 mg over the next 24 h)
Trial: 1713882
Drug: Dose-reduced induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-reduced induction therapy
Trial: 24865255
Drug: Standard induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard induction therapy
Trial: 25960303
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training (3-month home-based aerobic training program: 4 daily cycling sessions of 10 minutes each at 90% of heart rate at anaerobic threshold)
Trial: 25960303
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (standard therapy)
Trial: 12597703
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg MPH
Trial: 19920784
Drug: ivabradine 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivabradine 12.5 mg/day
Trial: 9169252
Drug: Low-dose pilocarpine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose pilocarpine treatment
Trial: 6511134
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal (2.5 g) administered immediately after the drugs
Trial: 6511134
Drug: Antacid (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid (20 ml of 8.5% magnesium hydroxide)
Trial: 30810400
Drug: Double trigger
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double trigger (GnRH agonist and hCG, 40 and 34 h prior to OPU)
Trial: 30810400
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist trigger (GnRHag 36 h before OPU and hCG on day of OPU)
Trial: 18779774
Drug: quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: quetiapine XR 600 mg/day
Trial: 18779774
Drug: quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: quetiapine XR 800 mg/day
Trial: 18779774
Drug: quetiapine IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: quetiapine IR 300 mg/day
Trial: 18779774
Drug: quetiapine IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: quetiapine IR 600 mg/day
Trial: 15967972
Drug: Liposomal lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal lidocaine 4% cream
Trial: 14601012
Drug: New procedure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New procedure for estimating treatment effects
Trial: 14601012
Drug: Conventional procedure
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Conventional procedure for estimating treatment effects
Trial: 1681265
Drug: Edmonston‐Zagreb high‐titre
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edmonston‐Zagreb high‐titre (EZ‐HT) vaccine at 5 months
Trial: 1681265
Drug: Schwarz high‐titre
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schwarz high‐titre (SW‐HT) vaccine at 5 months
Trial: 1681265
Drug: Placebo followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo followed by standard low‐titre Schwarz vaccine at 10 months (standard)
Trial: 31097853
Drug: Bupivacaine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (5 mL of 0.25%)
Trial: 21412231
Drug: Ketamine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (100 mg)
Trial: 31097853
Drug: Placebo (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5 cc distilled water)
Trial: 21576658
Drug: Dabigatran 110
RxNorm normalized name: dabigatran 110 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran 110 mg twice a day
Trial: 21576658
Drug: Dabigatran 150
RxNorm normalized name: dabigatran 150 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran 150 mg twice a day
Trial: 15716561
Drug: Expedited treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expedited treatment of sexual partners
Trial: 15716561
Drug: Expedited treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expedited treatment of sexual partners (gonorrhea)
Trial: 15716561
Drug: Expedited treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expedited treatment of sexual partners (chlamydial infection)
Trial: 12881083
Drug: Vaginal dinoprostone
RxNorm normalized name: dinoprostone Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal dinoprostone 6 mg every 6 hours (max 24 mg)
Trial: 12881083
Drug: Vaginal glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal glyceryl trinitrate 500 micrograms every 6 hours (max 2.5 mg)
Trial: 10437864
Drug: Immunisation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunisation with paternal mononuclear cells (treatment)
Trial: 8848700
Drug: 5-HT2-receptor antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5-HT2-receptor antagonist ketanserine
Trial: 29611536
Drug: Medium medical
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium medical ozone (40 μg/ml)
Trial: 29611536
Drug: Low medical
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low medical ozone (20 μg/ml)
Trial: 29611536
Drug: High medical
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High medical ozone (60 μg/ml)
Trial: 23911196
Drug: Taspoglutide 10
RxNorm normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taspoglutide 10 mg weekly (Taspo10)
Trial: 23911196
Drug: Taspoglutide 20
RxNorm normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taspoglutide 20 mg weekly (Taspo20)
Trial: 23911196
Drug: Exenatide 10
RxNorm normalized name: EXENATIDE 10MCG/DOSE 2.4ML 60D PEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide 10 mcg BID (Exe)
Trial: 19172548
Drug: Nasal testosterone
RxNorm normalized name: testosterone Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal testosterone 7.6mg, 15.2mg, or 22.8mg (single dose)
Trial: 19172548
Drug: Nasal testosterone
RxNorm normalized name: testosterone Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal testosterone 7.6mg (twice or three times a day)
Trial: 19172548
Drug: Nasal testosterone
RxNorm normalized name: testosterone Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal testosterone (all doses)
Trial: 9951570
Drug: Synthetic adrenocorticotropic
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic adrenocorticotropic hormone (ACTH)
Trial: 2190461
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) spray 1.25 mg
Trial: 2190461
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) spray 2.5 mg
Trial: 2190461
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) spray 5.0 mg
Trial: 378754
Drug: Colchicine 1
RxNorm normalized name: colchicine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 1 mg daily, 5 days a week
Trial: 29135865
Drug: Methylprednisolone administered
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone administered intravenously before cochlear implantation
Trial: 23453611
Drug: No steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No steroid administration (control group)
Trial: 29135865
Drug: Steroid administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Steroid administration
Trial: 21767798
Drug: Moderate to
RxNorm normalized name: GenTeal Moderate to Severe Ophthalmic Gel Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate to severe depression treatment
Trial: 19209097
Drug: MenACWY-CRM (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY-CRM (2 doses at 2 and 4 months of age)
Trial: 19209097
Drug: MenACWY-CRM (booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY-CRM (booster dose at 12 months)
Trial: 12642956
Drug: Fixed prostheses
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed prostheses on implants (upper jaw)
Trial: 12642956
Drug: Removable prostheses
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Removable prostheses on implants
Trial: 10721826
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy using topically applied delta‐aminolevulinic acid
Trial: 8958856
Drug: Paracetamol (PAR)
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol (PAR)
Trial: 1404352
Drug: Expectation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expectation of benefit from treatment
Trial: 69058
Drug: 14-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-valent pneumococcal polysaccharide vaccine
Trial: 31533777
Drug: Letrozole (LTZ)
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole (LTZ) 2.5 mg/day for 3 weeks
Trial: 31533777
Drug: Oral metronomic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metronomic vinorelbine (mVNB) 50 mg 3 days/week for 3 weeks
Trial: 31533777
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of LTZ and mVNB
Trial: 15965894
Drug: Albuterol 2.5
RxNorm normalized name: levalbuterol 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol 2.5 mg nebulized
Trial: 14727987
Drug: Trimetazidine 20
RxNorm normalized name: trimetazidine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine 20 mg, 3 times daily for 1 month
Trial: 9007781
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both phototherapy types
Trial: 26342738
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (100 mg/day)
Trial: 21655065
Drug: OAC (omeprazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC (omeprazole, amoxicillin, clarithromycin)
Trial: 28601610
Drug: OACB (omeprazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OACB (omeprazole, amoxicillin, clarithromycin, bismuth)
Trial: 28601610
Drug: OA+OCM (omeprazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OA+OCM (omeprazole, amoxicillin, metronidazole)
Trial: 28601610
Drug: OA+OCMB (omeprazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OA+OCMB (omeprazole, amoxicillin, metronidazole, bismuth)
Trial: 28601610
Drug: OA+OMDB (omeprazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OA+OMDB (omeprazole, amoxicillin, metronidazole, doxycycline, bismuth)
Trial: 26385671
Drug: Pain treatment
RxNorm normalized name: ARNICA MONTANA FLOWER 10 g in 50 g / SALIX ALBA BARK 15 g in 50 g / FRANKINCENSE 10 g in 50 g TOPICAL CREAM [HOUKEA Bone Pain Treatment Cream]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain treatment protocol and education program
Trial: 1332433
Drug: Interactional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactional therapy
Trial: 31900486
Drug: DNA administration
RxNorm normalized name: Toxoplasma gondii DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA administration by Biojector
Trial: 31241441
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy and vitamin D